Pricing Log in Create free account

Akari Therapeutics PLC (AKTX) vs Lipocine Inc. (LPCN)

Akari Therapeutics PLC and Lipocine Inc. are both Biotechnology companies. Akari Therapeutics PLC and Lipocine Inc. are of similar size ($13.6M and $12.6M). Akari Therapeutics PLC has the higher net margin (0.00% vs −249.2%) and the lower return on invested capital (−167.9% vs 0.00%). Across the 14 metrics below, Lipocine Inc. leads on 8 and Akari Therapeutics PLC on 6.

Valuation

Metric AKTX LPCN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 3.46 9.40
P/B 0.77 0.61 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.54 0.66
EV/Sales n/m (1.49) 9.02
Earnings yield (316.53%) (86.62%) (32.88%)
Free cash flow yield (75.80%) (78.12%) (23.13%)

Profitability

Metric AKTX LPCN Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (269.05%) 0.00%
Net margin 0.00% (249.16%) 0.00%
Free cash flow margin 0.00% (267.37%) 0.00%
Return on equity (140.09%) (52.86%) (51.96%)
Return on assets (69.16%) (47.52%) (46.06%)
Return on invested capital (167.93%) 0.00% 0.00%

Growth

Metric AKTX LPCN Biotechnology median
Revenue growth (TTM) — (13.36%) 6.76%
EPS growth (last fiscal year) 68.99% (93,988.89%) 29.88%
Revenue growth, 5-year CAGR — 64.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKTX LPCN Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 0.60 11.36 4.97
Net debt to EBITDA 0.27 1.42 1.01

Dividend

Metric AKTX LPCN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AKTX LPCN Biotechnology median
Market cap 13.56m 12.61m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack